We are live on ! Find out more
ILMN icon

Illumina

235.99 USD
-54.07
18.64%
At close Updated Oct 30, 4:00 PM EDT
Pre-market
After hours
236.54
+0.55
0.23%
1 day
-18.64%
5 days
-12.5%
1 month
-13.77%
3 months
15.07%
6 months
86.2%
Year to date
75.65%
1 year
138.35%
5 years
-41.8%
10 years
78.2%
 

About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Employees: 8,650

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 48%
Neutral 46%
Negative 6%
Positive
Zacks Investment Research
2 days ago
3 Promising Genomics Stocks to Add to Your Portfolio Now
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
3 Promising Genomics Stocks to Add to Your Portfolio Now
Neutral
Zacks Investment Research
2 days ago
ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth
Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth
Negative
Investors Business Daily
2 days ago
Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-Up
Illumina stock crashed Friday, despite beating third-quarter expectations, on tariff confusion and a shaky backdrop for AI-tied tech names.
Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-Up
Positive
Zacks Investment Research
3 days ago
Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to Say
Neutral
Seeking Alpha
3 days ago
Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
Positive
Zacks Investment Research
3 days ago
Illumina (ILMN) Q3 Earnings Beat Estimates
Illumina (ILMN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.34 per share a year ago.
Illumina (ILMN) Q3 Earnings Beat Estimates
Positive
MarketBeat
3 days ago
Illumina Q3 Earnings Call Highlights
Illumina NASDAQ: ILMN reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year revenue, operating-margin and earnings outlook, while executives said they remain on track toward longer-term growth targets.
Illumina Q3 Earnings Call Highlights
Neutral
Benzinga
3 days ago
Illumina Q3 2026 Earnings Call Transcript
Illumina (NASDAQ:ILMN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
Illumina Q3 2026 Earnings Call Transcript
Neutral
PRNewsWire
3 days ago
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
Positive
Seeking Alpha
4 days ago
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
Price charts implemented using Lightweight Charts™